Clinical Trial

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-19
notable Enrollment reduced: 316 -> 27 participants 2026-07-19
minor Completion moved earlier: 2026-06 -> 2026-04-01 2026-07-19
Trial Details
NCT Number NCT05024045
Lead Sponsor Eli Lilly and Company
Conditions Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell
Enrollment 27 participants
Start Date 2021-09-30
Primary Completion 2023-06-14 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-17